<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368039</url>
  </required_header>
  <id_info>
    <org_study_id>2019H0424</org_study_id>
    <nct_id>NCT04368039</nct_id>
  </id_info>
  <brief_title>Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis</brief_title>
  <official_title>Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Breitborde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with&#xD;
      first-episode psychosis: Effects on symptomatology and cognition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional deficits in prefrontal, limbic, and temporal regions of the brain are&#xD;
      well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may&#xD;
      contribute to such pathology, and effective functioning of mitochondrial activity in the&#xD;
      brain in dependent on a sufficient supply of oxygen. These data suggest that oxygen therapy&#xD;
      may improve symptoms in individuals with psychosis. This small pilot study will test this&#xD;
      hypothesis.&#xD;
&#xD;
      Individuals with first-episode psychosis will be randomized to receive either (i) 4 weeks of&#xD;
      nightly normobaric oxygen therapy (40% FiO2) or (ii) 4 weeks of a placebo condition utilizing&#xD;
      room air oxygen levels (21% FiO2). Participants will be blinded to what condition they&#xD;
      receive. Both conditions will be delivered via nasal cannula connected to oxygen&#xD;
      concentrators at five liters per minute (lpm), and participants will be instructed to&#xD;
      complete the intervention overnight while sleeping. At the end of the 4 week period, all&#xD;
      individuals will receive an additional 4 weeks of unblinded (i.e., &quot;open label&quot;) nightly&#xD;
      normobaric oxygen therapy (40% FiO2). Study assessments will be completed at (i) enrollment;&#xD;
      (ii) 4 weeks after enrollment, and (iii) 8 weeks after enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cognitive functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in social functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Global Functioning: Social Scale. Scores on this measure range from 1-10 with higher scores indicating greater social functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in role functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Global Functioning: Role Scale. Scores on this measure range from 1-10 with higher scores indicative of greater role functioning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in health-related quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the RAND 36-Item Health Survey.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in suicidality</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in occurrence in suicidal thoughts or behaviors as assessed using the Columbia Suicide Severity Rating Scale. This is a categorical rating scale that identifies the presence or absence of specific levels of severity of suicidal ideation and behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in substance use severity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the HABITS scale. This scale assesses the absolute values of use of specific substances (e.g., number of cigarettes smoked)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in service utilization</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Modified Service Use and Resources Form for Schizophrenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Pittsburgh Sleep Quality Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in medication adherence</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Medication Adherence rating Scale. Scores on this scale range from 0-10 with higher scores indicative of greater medication adherence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psychosis</condition>
  <condition>Schizophrenia</condition>
  <condition>First-episode Psychosis</condition>
  <arm_group>
    <arm_group_label>Normobaric Oxygen Therapy (40% FiO2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of nightly normobaric oxygen therapy (40% FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Normobaric Oxygen</intervention_name>
    <description>40% FiO2 for 4 weeks</description>
    <arm_group_label>Normobaric Oxygen Therapy (40% FiO2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>21% FiO2 for 4 weeks</description>
    <arm_group_label>Placebo Condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic&#xD;
             features as determined using the Structured Clinical Interview for the DSM-5.&#xD;
&#xD;
          -  Less than 5 years since the onset of frank psychotic symptoms as determined using the&#xD;
             Symptom Onset in Schizophrenia Inventory .&#xD;
&#xD;
          -  No evidence of a pre-existing intellectual disability defined as a premorbid IQ &gt;70 as&#xD;
             estimated using the Reading subtest of the Wide Range Achievement Test-4.&#xD;
&#xD;
          -  Ages 15-35&#xD;
&#xD;
          -  Non-smoker for past six months&#xD;
&#xD;
          -  Absence of suicidal ideation or behavior over the past month as assessed by the&#xD;
             Columbia Suicide Severity Rating Scale&#xD;
&#xD;
          -  The American Association for Respiratory Care notes that &quot;no absolute&#xD;
             contraindications to oxygen therapy exist when indications [for oxygen therapy] are&#xD;
             present.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Breitborde, PhD</last_name>
    <phone>(614) 685-6052</phone>
    <email>nicholas.breitborde@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harding Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Breitborde, PhD</last_name>
      <phone>614-685-6052</phone>
      <email>nicholas.breitborde@osumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004 Oct;110(4):243-56.</citation>
    <PMID>15352925</PMID>
  </reference>
  <reference>
    <citation>Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry. 2004 Apr 1;55(7):676-84.</citation>
    <PMID>15038995</PMID>
  </reference>
  <reference>
    <citation>Kann O, Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol. 2007 Feb;292(2):C641-57. Epub 2006 Nov 8. Review.</citation>
    <PMID>17092996</PMID>
  </reference>
  <reference>
    <citation>Bloch Y, Applebaum J, Osher Y, Amar S, Azab AN, Agam G, Belmaker RH, Bersudsky Y. Normobaric hyperoxia treatment of schizophrenia. J Clin Psychopharmacol. 2012 Aug;32(4):525-30. doi: 10.1097/JCP.0b013e31825d70b8.</citation>
    <PMID>22722511</PMID>
  </reference>
  <reference>
    <citation>First, M.B., et al., Structured Clinical Interview for DSM-5-Research Version2015, Arlington, VA: American Psychiatric Association.</citation>
  </reference>
  <reference>
    <citation>Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000 Jul 7;44(1):1-10.</citation>
    <PMID>10867307</PMID>
  </reference>
  <reference>
    <citation>Wilkinson, G.S. and G.J. Robertson, Wide Range Achievement Test (WRAT4)2006, Lutz, FL: PAR, Inc.</citation>
  </reference>
  <reference>
    <citation>Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.</citation>
    <PMID>22193671</PMID>
  </reference>
  <reference>
    <citation>AARC. AARC clinical practice guideline. Oxygen therapy in the home or alternate site health care facility--2007 revision &amp; update. Respir Care. 2007 Aug;52(8):1063-8.</citation>
    <PMID>17715561</PMID>
  </reference>
  <reference>
    <citation>Tandon R. Schizophrenia and other psychotic disorders in DSM-5. Clin Schizophr Relat Psychoses. 2013 Apr;7(1):16-9. doi: 10.3371/CSRP.TA.032513.</citation>
    <PMID>23538289</PMID>
  </reference>
  <reference>
    <citation>Auther, A., C. Smith, and B. Cornblatt, Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital, 2006.</citation>
  </reference>
  <reference>
    <citation>Niendam, T., et al., Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los Angeles, 2006.</citation>
  </reference>
  <reference>
    <citation>Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006 Dec;163(12):2080-9.</citation>
    <PMID>17151158</PMID>
  </reference>
  <reference>
    <citation>Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.</citation>
    <PMID>18172019</PMID>
  </reference>
  <reference>
    <citation>Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998 May;28(3):551-8.</citation>
    <PMID>9626712</PMID>
  </reference>
  <reference>
    <citation>Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000 May 5;42(3):241-7.</citation>
    <PMID>10785582</PMID>
  </reference>
  <reference>
    <citation>Hays, R.D., S. Prince-Embury, and H.Y. Chen, RAND-36 Health Status Inventory1998, San Antonio, TX: The Psychological Corporation.</citation>
  </reference>
  <reference>
    <citation>Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-81.</citation>
    <PMID>3774930</PMID>
  </reference>
  <reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.</citation>
    <PMID>2748771</PMID>
  </reference>
  <reference>
    <citation>Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.</citation>
    <PMID>15753237</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Nicholas Breitborde</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>psychosis</keyword>
  <keyword>treatment</keyword>
  <keyword>normobaric hyperoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

